|1.||Faro, Letícia V: 1 article (12/2015)|
|2.||Fintelman-Rodrigues, Natalia: 1 article (12/2015)|
|3.||Marques, Isakelly P: 1 article (12/2015)|
|4.||Souza, Thiago Moreno L: 1 article (12/2015)|
|5.||Nogueira, Christiane M: 1 article (12/2015)|
|6.||Brozeguini, Leonardo: 1 article (12/2015)|
|7.||Sacramento, Carolina Q: 1 article (12/2015)|
|8.||Santos-Filho, Osvaldo: 1 article (12/2015)|
|9.||de Souza, Maria Cecília B V: 1 article (12/2015)|
|10.||Boechat, Fernanda da C S: 1 article (12/2015)|
05/01/1989 - "These studies indicate good chemotherapeutic potential for the new generation fluorinated 4-quinolones in infections induced by the staphylococci, streptococci, Enterobacteriaceae and P. "
01/01/1985 - "Clinical studies on a possible role for some of the more recently synthesised 4-quinolones in the management of patients with respiratory infection are indicated."
01/01/1991 - "The 4-quinolones are also unusual because even for serious infections they can be given orally. "
05/01/1989 - "A number of new fluorinated 4-quinolones were compared in acute systemic mouse-infection models with various Gram-positive cocci (streptococci and staphylococci), Enterobacteriaceae and Pseudomonas aeruginosa. "
05/01/1989 - "Comparative chemotherapeutic activity of new fluorinated 4-quinolones and standard agents against a variety of bacteria in a mouse infection model."
10/01/1988 - "Comparative in vitro activity of the two new 4-quinolones S-25930 and S-25932 against gram-positive bacteria isolated from cancer patients."
01/01/1987 - "In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients."
03/26/1998 - "A novel series of 6,7,2',3',4'-substituted-1,2,3,4-tetrahydro-2-phenyl- 4-quinolones were synthesized and evaluated for interactions with tubulin and for cytotoxic activity against a panel of human tumor cell lines, including ileocecal carcinoma (HCT-8), breast cancer (MCF-7), lung carcinoma (A-549), epidermoid carcinoma of the nasopharynx (KB), renal cancer (CAKI-1), and melanoma cancer (SKMEL-2). "
01/01/1987 - "The in vitro activity of S-25930 and S-25932, two new 4-quinolones, against 450 aerobic gram-negative organisms isolated from cancer patients was evaluated and compared with the activity of ciprofloxacin, enoxacin, difloxacin (A-56619), and A-56620. "
|4.||Urinary Tract Infections (Urinary Tract Infection)
02/21/1986 - "New 4-quinolones in the treatment of urinary tract infections."
01/01/1988 - "Since the 4-quinolones do not cause marked ecological disturbances in the intestinal microflora, they may be suitable for selective decontamination in immunocompromised patients, for prophylaxis of urinary tract infections and for treatment of bacterial intestinal infections."
02/01/2005 - "The author recommends a categorization into four groups defined according to their spectrum of action and utilization: 1) preparations for the treatment of urinary tract infections; 2) systemically acting quinolones chiefly efficacious against Gram-negative bacteria; 3) so-called respiratory quinolones; and 4) quinolones with a very broad spectrum of action suitable for the treatment of very complicated infections. "
|5.||Typhoid Fever (Typhoid)
06/01/1993 - "The newer 4-quinolones can be recommended in multidrug resistant enteric fever in adults."
12/01/1990 - "Ciprofloxacin and other related fluorinated 4-quinolones have microbiological and pharmacokinetic properties that suggest they could be useful agents in the management of typhoid fever and bacterial gastroenteritis. "
|2.||Enoxacin (AT 2266)
|5.||S 25930 (ibafloxacin)